Indivior Pharmaceuticals Inc.
INDV Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS grew 580.0%, free cash flow grew 58.6% and total debt rose 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow INDV
Indivior Pharmaceuticals Inc. (INDV) Piotroski F-score
Indivior Pharmaceuticals Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (2.00) |
| FY2024 | 6 | 3.00 |
| FY2023 | 3 | (1.00) |
| FY2022 | 4 | (3.00) |
| FY2021 | 7 | 4.00 |
| FY2020 | 3 | (2.00) |
| FY2019 | 5 | (1.00) |
| FY2018 | 6 | (1.00) |
| FY2017 | 7 | 3.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 16.69% | 0.46% | Pass | 1 |
| Positive operating cash flow | (27.00m) | 36.00m | Fail | 0 |
| Rising return on assets | 16.69% | 0.46% | Pass | 1 |
| Cash flow above net income | (237.00m) | 29.00m | Fail | 0 |
| Falling long-term leverage | 0.23 | 0.20 | Fail | 0 |
| Rising current ratio | 0.71 | 0.90 | Fail | 0 |
| No new shares issued | 125,000,000 | 132,000,000 | Pass | 1 |
| Rising gross margin | 80.15% | 80.56% | Fail | 0 |
| Rising asset turnover | 0.98 | 0.77 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 8 |
| ALKS Alkermes plc compare | 7 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 7 |
| LQDA Liquidia Corporation compare | 5 |
| LNTH Lantheus Holdings, Inc. compare | 5 |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 4 |
| INDV Indivior Pharmaceuticals Inc. | 4 |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 3 |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover